Baker Brothers Life Sciences LP insider trades
Baker Brothers Life Sciences LP has filed 31 Form 4s with the SEC that we hold, for Incyte Corp (INCY) (Director, 10% owner), BeOne Medicines Ltd. (ONC) (Director), Kodiak Sciences Inc. (KOD) (Director, 10% owner) and IGMS (Director, 10% owner), among 13 companies in all. Across all of them we count 83 purchases worth $104.4M and 26 sales worth $456.1M reported on Form 4. In the last 12 months: 2 purchases ($60.0M) and 0 sales ($0). The largest single trade was a sale of 1,008,660 shares of BeOne Medicines Ltd. worth $182.1M, dated 2023-11-14. The first filing on our record is dated 2021-07-01 and the latest 2026-06-18.
Incyte Corp (INCY)
Director, 10% owner · 6 filings · 0 purchases and sales
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
BeOne Medicines Ltd. (ONC)
Director · 4 filings · 6 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2023-11-14 | S, sale reported on Form 4 | 1,008,660 | $182.1M | 2023-11-14 |
| 2023-11-14 | S, sale reported on Form 4 | 91,340 | $16.5M | 2023-11-14 |
| 2024-12-09 | S, sale reported on Form 4 | 83,036 | $15.5M | 2024-12-10 |
| 2024-12-09 | S, sale reported on Form 4 | 916,964 | $171.0M | 2024-12-10 |
| 2024-12-09 | S, sale reported on Form 4 | 3,074 | $639.4K | 2024-12-10 |
| 2024-12-09 | S, sale reported on Form 4 | 33,943 | $7.1M | 2024-12-10 |
Kodiak Sciences Inc. (KOD)
Director, 10% owner · 4 filings · 29 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-09-15 | P, purchase reported on Form 4 | 400 | $37.8K | 2021-09-17 |
| 2021-09-15 | P, purchase reported on Form 4 | 30,285 | $2.9M | 2021-09-17 |
| 2021-09-16 | P, purchase reported on Form 4 | 1,153 | $109.1K | 2021-09-17 |
| 2022-02-15 | P, purchase reported on Form 4 | 5,359 | $290.2K | 2022-02-17 |
| 2022-02-15 | P, purchase reported on Form 4 | 441 | $23.9K | 2022-02-17 |
| 2022-02-16 | P, purchase reported on Form 4 | 1,961 | $105.4K | 2022-02-17 |
| 2022-02-16 | P, purchase reported on Form 4 | 23,804 | $1.3M | 2022-02-17 |
| 2022-02-16 | P, purchase reported on Form 4 | 5,281 | $286.5K | 2022-02-17 |
| 2022-02-16 | P, purchase reported on Form 4 | 64,119 | $3.5M | 2022-02-17 |
| 2022-02-17 | P, purchase reported on Form 4 | 426 | $22.9K | 2022-02-17 |
| 2022-02-17 | P, purchase reported on Form 4 | 271,997 | $14.8M | 2022-02-17 |
| 2022-02-17 | P, purchase reported on Form 4 | 22,403 | $1.2M | 2022-02-17 |
| 2022-02-17 | P, purchase reported on Form 4 | 5,174 | $278.5K | 2022-02-17 |
| 2022-05-16 | P, purchase reported on Form 4 | 11,410 | $65.2K | 2022-05-18 |
| 2022-05-16 | P, purchase reported on Form 4 | 93,690 | $535.0K | 2022-05-18 |
| 2022-05-16 | P, purchase reported on Form 4 | 1,846 | $10.6K | 2022-05-18 |
| 2022-05-16 | P, purchase reported on Form 4 | 15,154 | $87.1K | 2022-05-18 |
| 2022-05-17 | P, purchase reported on Form 4 | 8,118 | $48.6K | 2022-05-18 |
| 2022-05-17 | P, purchase reported on Form 4 | 989 | $5.9K | 2022-05-18 |
| 2022-05-17 | P, purchase reported on Form 4 | 11,043 | $66.1K | 2022-05-18 |
| 2022-05-17 | P, purchase reported on Form 4 | 90,674 | $543.1K | 2022-05-18 |
| 2022-05-18 | P, purchase reported on Form 4 | 7,489 | $44.7K | 2022-05-18 |
| 2022-05-18 | P, purchase reported on Form 4 | 1,115 | $6.6K | 2022-05-18 |
| 2022-05-18 | P, purchase reported on Form 4 | 9,157 | $54.5K | 2022-05-18 |
| 2022-05-18 | P, purchase reported on Form 4 | 22,266 | $132.9K | 2022-05-18 |
| 2022-05-18 | P, purchase reported on Form 4 | 182,827 | $1.1M | 2022-05-18 |
| 2022-05-18 | P, purchase reported on Form 4 | 912 | $5.4K | 2022-05-18 |
| 2025-12-18 | P, purchase reported on Form 4 | 217,428 | $5.0M | 2025-12-19 |
| 2025-12-18 | P, purchase reported on Form 4 | 2,391,268 | $55.0M | 2025-12-19 |
IGMS
Director, 10% owner · 3 filings · 12 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2023-12-13 | P, purchase reported on Form 4 | 769 | $4.4K | 2023-12-15 |
| 2023-12-13 | P, purchase reported on Form 4 | 9,649 | $55.6K | 2023-12-15 |
| 2023-12-13 | P, purchase reported on Form 4 | 5,679 | $34.0K | 2023-12-15 |
| 2023-12-13 | P, purchase reported on Form 4 | 71,219 | $426.6K | 2023-12-15 |
| 2023-12-14 | P, purchase reported on Form 4 | 11,621 | $75.5K | 2023-12-15 |
| 2023-12-14 | P, purchase reported on Form 4 | 145,749 | $947.4K | 2023-12-15 |
| 2023-12-15 | P, purchase reported on Form 4 | 15 | $95 | 2023-12-15 |
| 2023-12-15 | P, purchase reported on Form 4 | 185 | $1.2K | 2023-12-15 |
| 2023-12-15 | P, purchase reported on Form 4 | 4,188 | $26.7K | 2023-12-15 |
| 2023-12-15 | P, purchase reported on Form 4 | 52,528 | $334.6K | 2023-12-15 |
| 2023-12-15 | P, purchase reported on Form 4 | 17,066 | $112.6K | 2023-12-15 |
| 2023-12-15 | P, purchase reported on Form 4 | 214,025 | $1.4M | 2023-12-15 |
Madrigal Pharmaceuticals, INC. (MDGL)
Director · 3 filings · 30 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2023-11-17 | P, purchase reported on Form 4 | 39 | $6.7K | 2023-11-21 |
| 2023-11-17 | P, purchase reported on Form 4 | 1,107 | $186.8K | 2023-11-21 |
| 2023-11-17 | P, purchase reported on Form 4 | 350 | $60.6K | 2023-11-21 |
| 2023-11-17 | P, purchase reported on Form 4 | 4,151 | $719.0K | 2023-11-21 |
| 2023-11-17 | P, purchase reported on Form 4 | 140 | $24.3K | 2023-11-21 |
| 2023-11-17 | P, purchase reported on Form 4 | 1,660 | $288.4K | 2023-11-21 |
| 2023-11-17 | P, purchase reported on Form 4 | 82 | $14.3K | 2023-11-21 |
| 2023-11-17 | P, purchase reported on Form 4 | 978 | $170.8K | 2023-11-21 |
| 2023-11-17 | P, purchase reported on Form 4 | 1,528 | $267.2K | 2023-11-21 |
| 2023-11-17 | P, purchase reported on Form 4 | 18,125 | $3.2M | 2023-11-21 |
| 2023-11-17 | P, purchase reported on Form 4 | 415 | $72.9K | 2023-11-21 |
| 2023-11-17 | P, purchase reported on Form 4 | 4,923 | $865.1K | 2023-11-21 |
| 2023-11-17 | P, purchase reported on Form 4 | 903 | $158.8K | 2023-11-21 |
| 2023-11-17 | P, purchase reported on Form 4 | 10,715 | $1.9M | 2023-11-21 |
| 2023-11-17 | P, purchase reported on Form 4 | 54 | $9.1K | 2023-11-21 |
| 2023-11-17 | P, purchase reported on Form 4 | 646 | $108.3K | 2023-11-21 |
| 2023-11-17 | P, purchase reported on Form 4 | 93 | $15.7K | 2023-11-21 |
| 2023-11-17 | P, purchase reported on Form 4 | 461 | $79.2K | 2023-11-21 |
| 2023-11-20 | P, purchase reported on Form 4 | 153 | $27.8K | 2023-11-21 |
| 2023-11-20 | P, purchase reported on Form 4 | 1,847 | $336.0K | 2023-11-21 |
| 2023-11-20 | P, purchase reported on Form 4 | 579 | $106.2K | 2023-11-21 |
| 2023-11-20 | P, purchase reported on Form 4 | 7,010 | $1.3M | 2023-11-21 |
| 2023-11-20 | P, purchase reported on Form 4 | 100 | $18.6K | 2023-11-21 |
| 2023-11-20 | P, purchase reported on Form 4 | 1,206 | $224.2K | 2023-11-21 |
| 2023-11-20 | P, purchase reported on Form 4 | 405 | $75.9K | 2023-11-21 |
| 2023-11-20 | P, purchase reported on Form 4 | 4,895 | $917.1K | 2023-11-21 |
| 2023-11-20 | P, purchase reported on Form 4 | 95 | $17.9K | 2023-11-21 |
| 2023-11-20 | P, purchase reported on Form 4 | 1,147 | $216.6K | 2023-11-21 |
| 2023-11-20 | P, purchase reported on Form 4 | 250 | $47.4K | 2023-11-21 |
| 2023-11-20 | P, purchase reported on Form 4 | 3,022 | $573.3K | 2023-11-21 |
Kiniksa Pharmaceuticals International, plc (KNSA)
Director · 2 filings · 0 purchases and sales
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Neurogene Inc. (NLTX)
Director, 10% owner · 2 filings · 12 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2023-08-15 | P, purchase reported on Form 4 | 4,342 | $2.9K | 2023-08-17 |
| 2023-08-15 | P, purchase reported on Form 4 | 143,519 | $90.4K | 2023-08-17 |
| 2023-08-15 | P, purchase reported on Form 4 | 1,740,581 | $1.1M | 2023-08-17 |
| 2023-08-15 | P, purchase reported on Form 4 | 358 | $240 | 2023-08-17 |
| 2023-08-16 | P, purchase reported on Form 4 | 4,434 | $3.0K | 2023-08-17 |
| 2023-08-16 | P, purchase reported on Form 4 | 17,124 | $11.6K | 2023-08-17 |
| 2023-08-16 | P, purchase reported on Form 4 | 207,676 | $141.2K | 2023-08-17 |
| 2023-08-16 | P, purchase reported on Form 4 | 366 | $249 | 2023-08-17 |
| 2023-08-17 | P, purchase reported on Form 4 | 61,134 | $42.2K | 2023-08-17 |
| 2023-08-17 | P, purchase reported on Form 4 | 5,041 | $3.5K | 2023-08-17 |
| 2023-08-17 | P, purchase reported on Form 4 | 93,091 | $64.2K | 2023-08-17 |
| 2023-08-17 | P, purchase reported on Form 4 | 7,676 | $5.3K | 2023-08-17 |
Prelude Therapeutics Inc (PRLD)
Director, 10% owner · 2 filings · 0 purchases and sales
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Acadia Pharmaceuticals INC (ACAD)
Director, 10% owner · 1 filing · 0 purchases and sales
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
DBV Technologies S.A. (DBVT)
Director, 10% owner · 1 filing · 0 purchases and sales
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Denali Therapeutics Inc. (DNLI)
Director · 1 filing · 0 purchases and sales
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
SGEN
Director, 10% owner · 1 filing · 20 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-11-30 | S, sale reported on Form 4 | 540 | $86.4K | 2021-12-02 |
| 2021-11-30 | S, sale reported on Form 4 | 9,618 | $1.6M | 2021-12-02 |
| 2021-11-30 | S, sale reported on Form 4 | 93 | $15.4K | 2021-12-02 |
| 2021-11-30 | S, sale reported on Form 4 | 1,007 | $166.8K | 2021-12-02 |
| 2021-11-30 | S, sale reported on Form 4 | 19,226 | $3.1M | 2021-12-02 |
| 2021-11-30 | S, sale reported on Form 4 | 208,597 | $33.4M | 2021-12-02 |
| 2021-11-30 | S, sale reported on Form 4 | 886 | $146.0K | 2021-12-02 |
| 2021-11-30 | S, sale reported on Form 4 | 5,860 | $938.1K | 2021-12-02 |
| 2021-11-30 | S, sale reported on Form 4 | 2,713 | $435.5K | 2021-12-02 |
| 2021-11-30 | S, sale reported on Form 4 | 29,432 | $4.7M | 2021-12-02 |
| 2021-11-30 | S, sale reported on Form 4 | 1,858 | $299.1K | 2021-12-02 |
| 2021-11-30 | S, sale reported on Form 4 | 20,154 | $3.2M | 2021-12-02 |
| 2021-11-30 | S, sale reported on Form 4 | 123 | $20.1K | 2021-12-02 |
| 2021-11-30 | S, sale reported on Form 4 | 1,337 | $218.5K | 2021-12-02 |
| 2021-12-01 | S, sale reported on Form 4 | 51,399 | $8.3M | 2021-12-02 |
| 2021-12-01 | S, sale reported on Form 4 | 4,738 | $764.7K | 2021-12-02 |
| 2021-12-01 | S, sale reported on Form 4 | 8,332 | $1.3M | 2021-12-02 |
| 2021-12-01 | S, sale reported on Form 4 | 768 | $123.9K | 2021-12-02 |
| 2021-12-01 | S, sale reported on Form 4 | 25,833 | $4.2M | 2021-12-02 |
| 2021-12-01 | S, sale reported on Form 4 | 2,381 | $382.9K | 2021-12-02 |
TLIS
Director, 10% owner · 1 filing · 0 purchases and sales
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Source
Counted from the Form 4 filings this reporting owner (SEC CIK 1363364) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms